Medtronic contribution to EU Public Procurement consultation on the evaluation of the EUs Public Procurement Directives (Directive 2014/23/EU on the award of concession contracts Directive 2014/24/EU on public procurement) Medtronic is a global leader in medical technology, services, and solutions. More than 70 conditions in the human body are treated with our therapies.
MED
Medtronic
Company · Ireland · EU Transparency Register 326347337793-89
4
positions filed
in the 665 files tracked
3
legislative files
of 665 tracked
2
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1210 companies & groups on this site, they rank #449 by legislative files engaged, a count of participation, not a measure of influence.
1.2
declared lobbying FTE
self-declared
€500K+
declared costs / yr (floor)
2
EP accreditations
as declared to the register
2020
in the register since
Declares membership of
- MedTech Europe www.medtecheurope.org
- European Justice Forum www.europeanjusticeforum.org
- Friends of Europe www.friendsofeurope.org
- EFPIA (Partner in Research) www.efpia.eu
- Information Technology Industry Council, ITI www.itic.org
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026).
- Register category
- Companies & groups
- Head office
- Galway, Ireland
- EU office
- Jette
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Medtronic in PolicySpeak: request access →
Work at Medtronic? so we know who speaks for it.
Their record over time
Medtronic filed 4 positions between 6 Aug 2021 and 1 Aug 2026, across 3 of the 665 legislative files tracked here, attaching a full position paper 2 times.
2021 · 1 filed2025 · 2 filed2026 · 1 filed
What they argued
Medtronic welcomes the European Commission's targeted revision of the Medical Device Regulation (MDR) and supports its overarching objectives to strengthen the European regulatory framework while improving its efficiency and predictability.
Medtronic welcomes the European Commission's initiative to implement the targeted review in 2025. While the Medical Device Regulation rules were aimed to improve safety, quality and transparency, they added costs and administrative burden that had slowed down innovation in the EU compared to other regions, risking delayed patient access to devices.
MEDTRONIC SUBMISSION Ref. Ares(2021)5002783 - 06/08/2021 ARTIFICAL INTELLIGENCE REGULATION AUGUST 2021 Executive Summary Medtronic, as a global leader in medical technology, strongly supports the principle of EU-wide regulation of Artificial Intelligence (AI) and welcomes the Commission’s vision to turn Europe into a global hub for AI and further develop a resilient Europe fit for the Digital Decade.
Opening of the attached position paper · the full paper is on the Commission’s record (source link above)
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put Medtronic next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Showing 5 of 59.
Is this your organization?
Everything on this page comes from Medtronic’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.